10:11 AM EST - Thallion Pharmaceuticals Inc : announced today that it has temporarily suspended the screening and enrollment of the high dose cohort of its Phase II SHIGATEC study as a precautionary measure due to a preliminary product out-of-specification finding observed during routine stability testing of its anti-Stx1 monoclonal antibody. Thallion Pharmaceuticals Inc
shares T.TLN are trading down $0.01 at $0.17.
